Posted by Michael Wonder on 04 Jan 2021
FDA grants ARX788 fast track designation for HER2 positive metastatic breast cancer
4 January 2021 - Ambrx announced that the U.S. FDA granted ARX788 fast track designation as monotherapy for the treatment of advanced or metastatic HER2 positive breast cancer patients who have received one or more prior anti-HER2 based regimens in the metastatic setting.
ARX788 is a homogeneous and highly stable antibody drug conjugate targeting the HER2 receptor.
